Amniotic fluid embolism: an evidence-based review
- PMID: 19879393
- PMCID: PMC3401570
- DOI: 10.1016/j.ajog.2009.04.052
Amniotic fluid embolism: an evidence-based review
Erratum in
- Am J Obstet Gynecol. 2010 Jan;202(1):92
Abstract
We conducted an evidence-based review of information about [corrected] amniotic fluid embolism (AFE). The estimated incidence of AFE is 1:15,200 and 1:53,800 deliveries in North America and Europe, respectively. The case fatality rate and perinatal mortality associated with AFE are 13-30% and 9-44%, respectively. Risk factors associated with an [corrected] increased risk of AFE include advanced maternal age, placental abnormalities, operative deliveries, eclampsia, polyhydramnios, cervical lacerations, [corrected] and uterine rupture. The hemodynamic response in [corrected] AFE is biphasic, with initial pulmonary hypertension and right ventricular failure, followed by left ventricular failure. Promising therapies include selective pulmonary vasodilators and recombinant activated factor VIIa. Important topics for future research are presented.
References
-
- Meyer JR. Embolia pulmonar amnio caseosa. Bra Med. 1926;2:301–3.
-
- Steiner PE, Lushbaugh CC. Maternal pulmonary embolism by amniotic fluid as a cause of obstetric shock and unexpected deaths in obstetrics. JAMA. 1941;117:1245–54. 1341–5. - PubMed
-
- Lang CT, King JC. Maternal mortality in the United States. Best Pract Res Clin Obstet Gynaecol. 2008;22:517–31. - PubMed
-
- Stroup DF, Berlin JA, Morton SC, et al. Metanalysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
